American Heart Month - BCI and Endokinase

It is important for everyone to know that leading cardiologists recognize the need for effective anti-platelet therapies and also to see that the newest drug in this category is WORSE than useless.

Please learn all that you can about why Essential Daily Defense has been associated with such dramatic reduction in heart attacks and strokes (Heparin-like activity due to the effect of EDTA on sulfated polysaccharides). Also know that the full therapeutic dose of NATTOKINASE (Endokinase) requires 2 caps bid containing 1000 FU per cap and that this MORE than doubles the monthly cost of PREVENTING heart attacks and strokes over JUST using Beyond Chelation-Improved, one packet am and pm.

Thus we MUST use judgment in helping to decide WHERE and WHEN to augment the proven protection offered with just the BC-I daily, since we all agree everyone that we see deserves to be on a high potency Multiple Vitamin Mineral each day. The Essential Fatty Acid deficiency is PROVEN to be epidemic in our country, so that it is not a question of EITHER BC-I OR ENDOKINASE (or Endozym when you ALSO need anti-inflammatory activity from the proven effective added components in Endozym) but it boils down to which patients are sufficiently motivated to be on BOTH the BC-I and a Nattokinase product like Endozym or Endokinase.

Technically we could justify recommending a Nattokinase enzyme product to virtually anyone who is not menstruating regularly now that we have the research by Dr. Kensey about HOW important it is to maintain LOW blood viscosity. Yet how many can afford BOTH of these important dietary supplement interventions on a daily basis year after year?

We will gain more experience with IN-OFFICE blood viscosity testing now that the RHEOLOGICS device can be in everyone's office for just $100 a month. That along with a good history AND full knowledge of the patient's entire vascular condition can help us decide where and when we need both. Further coagulation testing as offered by www.thrombocare.com will often be indicated in arrhythmias or where a history of coagulation problems is elicited, either in the patient or the immediate family.

Garry F. Gordon, MD,DO,MD(H)

New England Journal of MedicineVolume 350:232-238
January 15, 2004 Number 3

A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel

Adnan Kastrati, M.D., Julinda Mehilli, M.D., Helmut Schühlen, M.D., Josef Dirschinger, M.D., Franz Dotzer, M.D., Jurriën M. ten Berg, M.D., Franz-Josef Neumann, M.D., Hildegard Bollwein, M.D., Christian Volmer, Meinrad Gawaz, M.D., Peter B. Berger, M.D., Albert Schömig, M.D., for the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators

ABSTRACT

Background
Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown.

Methods
We enrolled 2159 patients with coronary artery disease who underwent a percutaneous coronary intervention: 1079 patients were randomly assigned in a double-blind manner to receive abciximab and 1080 patients to receive placebo. All patients were pretreated with a 600-mg dose of clopidogrel at least two hours before the procedure. The primary end point of the trial was the composite of death, myocardial infarction, and urgent target-vessel revascularization within 30 days after randomization.

Results
The incidence of the primary end point was 4 percent (45 patients) in the abciximab group, as compared with 4 percent (43 patients) in the placebo group (relative risk, 1.05; 95 percent confidence interval, 0.69 to 1.59; P=0.82). Most adverse events were myocardial infarctions: the incidence was 4 percent (40 patients) in the abciximab group and 4 percent (41 patients) in the placebo group (P=0.91). Twelve patients (1 percent) in the abciximab group and eight patients (1 percent) in the placebo group had major bleeding complications (P=0.37). Profound thrombocytopenia occurred in 10 patients (1 percent) in the abciximab group but in none in the placebo group (P=0.002).

Conclusions
Our data suggest that in patients at low-to-intermediate risk who undergo elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel, abciximab is associated with no clinically measurable benefit within the first 30 days.

For complex medical questions, we advise that you make an appointment for a personal, recorded, telephonic consultation with me. Each consultation is recorded and provided to you on audio CD. To schedule an appointment, call (928) 472-4263, Monday through Friday, during standard business hours.